NCT00106535View on ClinicalTrials.gov

A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,196

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

May 31, 2007

Study Completion Date

July 31, 2012

Conditions
Rheumatoid Arthritis
Interventions
DRUG

tocilizumab [RoActemra/Actemra]

4 mg/kg or 8 mg/kg IV/month every 4 weeks.

DRUG

Placebo

IV/month

DRUG

Methotrexate

10-25 mg/week

Trial Locations (152)

1011

Lausanne

1862

Diepkloof

2139

St Leonards

2305

New Lambton

2609

Lillehammer

2900

Hellerup

3144

Malvern

3168

Melbourne

4001

Cape Town

5000

Odense

5011

Adelaide

5528

Haugesund

6008

Shenton Park

7405

Cape Town

7500

Cape Town

9007

Sankt Gallen

9038

Tromsø

10016

New York

10128

Torino

11009

Cadiz

11042

Lake Success

11201

Brooklyn

11527

Athens

12206

Albany

15121

Athens

15127

Athens

16132

Genova

16635

Duncansville

18015

Bethlehem

18120

Heinola

19140

Philadelphia

19610

Wyomissing

20122

Milan

20157

Milan

20902

Wheaton

21100

Varese

21702

Frederick

21740

Hagerstown

25123

Brescia

27100

Pavia

27609

Raleigh

28211

Charlotte

28401

Wilmington

28801

Asheville

29204

Columbia

31000

Chihuahua City

31059

Toulouse

33076

Bordeaux

33100

Udine

33180

Aventura

33334

Fort Lauderdale

33407

West Palm Beach

33614

Tampa

35128

Padua

35801

Huntsville

37067

Valeggio sul Mincio

37134

Verona

37203

Nashville

39008

Santander

40515

Lexington

41009

Seville

42100

Reggio Emilia

44718

Canton

45000

Orléans

50139

Florence

53217

Glendale

54511

Vandœuvre-lès-Nancy

56100

Pisa

59037

Lille

59101

Billings

59802

Missoula

61103

Rockford

63131

St Louis

63141

St Louis

64460

Monterrey

67098

Strasbourg

67100

Coppito

71110

Heraklion

73109

Oklahoma City

74135

Tulsa

75231

Dallas

75651

Paris

75877

Paris

76233

Bois-Guillaume

78217

San Antonio

80054

Amiens

80131

Napoli

80230

Denver

80304

Boulder

80910

Colorado Springs

83404

Idaho Falls

83642

Meridan

83702

Boise

83814

Coeur d'Alene

85000

Obregón

85251

Scottsdale

85724

Tucson

89502

Reno

90029

Oulu

90095

Los Angeles

90505

Torrance

90806

Long Beach

92108

San Diego

92801

Anaheim

93009

Bobigny

93454

Santa Maria

94118

San Francisco

94270

Le Kremlin-Bicêtre

97401

Eugene

97500

Mérida

98104

Seattle

98502

Olympia

100032

Beijing

100044

Beijing

200127

Shanghai

200433

Shanghai

210008

Nanjing

5403900

São Paulo

35233-7333

Birmingham

60612-3824

Chicago

46202-5100

Indianapolis

03820

Dover

08055

Medford

08043

Voorhees Township

11794-8161

Stony Brook

91350-200

Porto Alegre

20551-030

Rio de Janeiro

01221-020

São Paulo

04026-000

São Paulo

00290

Helsinki

01400

Vantaa

06202

Nice

00161

Roma

03100

Mexico City

06700

Mexico City

06726

Mexico City

07360

Mexico City

85-168

Bydgoszcz

13-200

Działdowo

82-300

Elblag

62-800

Kalisz

30-119

Krakow

30-510

Krakow

60-218

Poznan

71-252

Szczecin

43-450

Ustroń

00-909

Warsaw

02-637

Warsaw

00716

Ponce

00936-5067

San Juan

08036

Barcelona

08208

Sabadell

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00106535 - A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA) | Biotech Hunter | Biotech Hunter